We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempur Sealy International, Inc. (TPX - Free Report) , is involved in the development, manufacturing and marketing of bedding products primarily in North America and internationally. Shares have soared over 80% during the last year to crush its industry’s average and the S&P 500. The mattress powerhouse returned to sales growth in 2018 and its expansion looks poised to continue as it proves it’s ready to fight off challenges from digital upstarts through its own direct-to-consumer expansion and more. Tempur Sealy topped our Q3 earnings and revenues estimates, with adjusted earnings up 28% and sales up 12.5%. Both TPX’s top and bottom line expansions marked the sixth consecutive quarter of growth for the firm.
Delta Air Lines (DAL - Free Report) , is a leading provider of scheduled air transportation for passengers and cargo throughout the United States and around the world. Delta is being aided by a healthy uptick in passenger revenues on the back of strong demand for air travel. Reduction in fuel prices is an added positive. Further, we are upbeat about Delta's efforts to reward its shareholders through dividends and buybacks. Anticipating demand to remain strong, Delta issued a bullish earnings per share projection for 2020. Backed by these tailwinds, shares of Delta outperformed its industry in a year's time.
Treakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Top Stock Picks for Week of January 13, 2020
Tempur Sealy International, Inc. (TPX - Free Report) , is involved in the development, manufacturing and marketing of bedding products primarily in North America and internationally. Shares have soared over 80% during the last year to crush its industry’s average and the S&P 500. The mattress powerhouse returned to sales growth in 2018 and its expansion looks poised to continue as it proves it’s ready to fight off challenges from digital upstarts through its own direct-to-consumer expansion and more. Tempur Sealy topped our Q3 earnings and revenues estimates, with adjusted earnings up 28% and sales up 12.5%. Both TPX’s top and bottom line expansions marked the sixth consecutive quarter of growth for the firm.
Delta Air Lines (DAL - Free Report) , is a leading provider of scheduled air transportation for passengers and cargo throughout the United States and around the world. Delta is being aided by a healthy uptick in passenger revenues on the back of strong demand for air travel. Reduction in fuel prices is an added positive. Further, we are upbeat about Delta's efforts to reward its shareholders through dividends and buybacks. Anticipating demand to remain strong, Delta issued a bullish earnings per share projection for 2020. Backed by these tailwinds, shares of Delta outperformed its industry in a year's time.
Treakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>